ALK and IGF-1R as independent targets in crizotinib resistant lung cancer

ALK positive non-small cell lung cancer is highly responsive to ALK inhibitors such as crizotinib, but drug resistance typically develops within a year of treatment. In this study we investigated whether IGF-1R is an independent druggable target in ALK-positive lung cancer cells. We confirmed that c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Christabel, Nimick, Mhairi, Nehoff, Hayley, Ashton, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654778/
https://www.ncbi.nlm.nih.gov/pubmed/29066738
http://dx.doi.org/10.1038/s41598-017-14289-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654778/
https://www.ncbi.nlm.nih.gov/pubmed/29066738
http://dx.doi.org/10.1038/s41598-017-14289-w

Ejemplares similares